{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Signal-Detection-Pharmacovigilance-Processes”
},
“headline”: “SOP for Signal Detection and Pharmacovigilance Processes in Clinical Trials”,
“description”: “This SOP defines procedures for signal detection and pharmacovigilance processes in clinical trials, ensuring safety monitoring, early identification of risks, and compliance with ICH, FDA, EMA, CDSCO, and WHO regulations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 21/12/2025
Standard Operating Procedure for Signal Detection and Pharmacovigilance Processes
| Department | Clinical Research |
| SOP No. | CR/PV/047/2025 |
| Supersedes | NA |
| Page No. | 1 of 22 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to establish clear procedures for detecting, evaluating, and managing safety signals during clinical trials. Signal detection is a critical component of pharmacovigilance,
Scope
This SOP applies to sponsors, investigators, pharmacovigilance teams, and CROs responsible for safety monitoring in clinical trials. It covers data collection, trend analysis, signal detection, validation, evaluation, prioritization, reporting, and risk minimization measures.
Responsibilities
- Principal Investigator (PI): Reports adverse events promptly and provides clinical input for signal evaluation.
- Pharmacovigilance Officer: Conducts signal detection analysis, validates signals, and ensures compliance with regulatory timelines.
- Sponsor/CRO: Oversees global safety monitoring, ensures regulatory reporting, and implements CAPA where required.
- Quality Assurance Officer: Audits pharmacovigilance processes and ensures SOP compliance during inspections.
Accountability
The sponsor is accountable for pharmacovigilance signal detection and ensuring global regulatory compliance. The PI remains accountable for accurate reporting of adverse events from the site.
Procedure
1. Data Collection
Collect adverse event (AE) and serious adverse event (SAE) data from sites, safety databases, and literature sources.
Ensure data integrity and compliance with ALCOA+ principles.
2. Signal Detection
Perform routine data mining and disproportionality analysis using validated safety systems.
Identify unusual patterns or clusters of adverse events that may represent a signal.
3. Signal Validation
Confirm whether the identified event is a true signal based on case quality, biological plausibility, and consistency across sources.
Document validation outcomes in Signal Validation Log (Annexure-1).
4. Signal Evaluation
Assess the signal in terms of causality, severity, frequency, and public health impact.
Obtain expert medical review where necessary.
5. Signal Prioritization
Classify signals as high, medium, or low priority based on clinical impact.
Document prioritization in Signal Prioritization Record (Annexure-2).
6. Signal Reporting
Report validated and significant signals to regulatory authorities as per ICH E2E guidelines.
File records in TMF and ISF.
7. Corrective and Preventive Actions (CAPA)
Implement CAPA for signals requiring intervention (e.g., updated risk management plan, protocol amendment).
8. Archiving
Archive signal detection records for a minimum of 10 years or as per global regulations.
Abbreviations
- SOP: Standard Operating Procedure
- PI: Principal Investigator
- Pv: Pharmacovigilance
- AE: Adverse Event
- SAE: Serious Adverse Event
- CAPA: Corrective and Preventive Action
- CRO: Clinical Research Organization
- QA: Quality Assurance
- TMF: Trial Master File
- ISF: Investigator Site File
Documents
- Signal Validation Log (Annexure-1)
- Signal Prioritization Record (Annexure-2)
- Signal Reporting Log (Annexure-3)
References
- ICH E2E – Pharmacovigilance Planning
- US FDA – Signal Detection Guidance
- EMA – Signal Management Guidelines
- CDSCO – Pharmacovigilance and Signal Reporting
- WHO – Signal Detection in Pharmacovigilance
Version: 1.0
Approval Section
| Prepared By | Rajesh Kumar, Pharmacovigilance Officer |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Principal Investigator |
Annexures
Annexure-1: Signal Validation Log
| Date | Signal Description | Validated? | Outcome | Validated By |
|---|---|---|---|---|
| 12/09/2025 | Unexpected liver enzyme elevations | Yes | Signal Confirmed | PV Officer |
Annexure-2: Signal Prioritization Record
| Date | Signal | Priority | Rationale | Reviewed By |
|---|---|---|---|---|
| 15/09/2025 | Liver enzyme elevations | High | Potential risk of hepatotoxicity | QA Officer |
Annexure-3: Signal Reporting Log
| Date | Signal Reported | Authority | Submission Method | Acknowledgment |
|---|---|---|---|---|
| 20/09/2025 | Hepatotoxicity Signal | EMA | EudraVigilance | Yes |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head, Clinical Research |
For more SOPs visit: Pharma SOP